The position paper on Component D fraud can be foundhere.. PRESS RELEASE Alexandria, Va., Jan. 29, 2015 —The Academy of Managed Care Pharmacy applauds two crucial provisions in draft legislation issued this week by the House Energy and Commerce Committee that combat the abuse of controlled substances and payment fraud in the Medicare Part D prescription drug benefit program. AMCP Chief Executive Officer Edith A. Rosato, RPh, IOM issued the following statement: The Academy is pleased the Committee’s expenses includes Sec. 4281, which demands creating safe pharmacy systems in Part D to prevent the diversion and misuse of controlled substances, and Sec. 4282, which authorizes Part D programs to suspend payment of statements to pharmacies suspected of a credible allegation of fraud.Interim Analyses and Data Monitoring An unbiased data and safety monitoring committee met twice yearly; two formal interim analyses were conducted when approximately one third and two thirds of the total primary composite events had happened. At the second interim efficacy analysis and the 7th interim safety evaluation , the independent data and safety monitoring committee suggested termination of the analysis medication, based on their assessment that the excess threat of adverse occasions in the aliskiren group could not become offset by a decrease in major cardiovascular and renal occasions .